Completed PHASE2 INTERVENTIONAL 1-arm NCT00821327

Gemzar, Cisp, Sunitinib Urothelial Ca

Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients With Advanced/Metastatic Urothelial Carcinoma

Sponsor: Pfizer

Interventions Gemcitabine, Cisplatin, Sunitinib

Updated 8 times since 2017 Last updated: Sep 15, 2016 Started: Aug 31, 2008 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00821327, this PHASE2 trial focuses on Urothelial Cancer and remains completed. Sponsored by Pfizer, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

Given the strong preclinical rationale for targeting angiogenesis in urothelial carcinoma (UC), the evidence supporting co-targeting of VEGFR2 and PDGF, the safety and efficacy of single-agent sunitinib in patients with UC, and preclinical evidence of synergy with the combination of sunitinib and cisplatin, the evaluation of sunitinib in combination with gemcitabine plus cisplatin in previously untreated patients with metastatic UC is warranted.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
US Oncology Research

Data source: US Oncology Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Albany, United States , Amarillo, United States , Arlington, United States , Austin, United States , Beaumont, United States , Bedford, United States , Burien, United States , Chicago, United States , Columbia, United States and 35 more locations